Vitiligo Drug Breakthrough: Phase 3 Tranquillo results show oral ritlecitinib (100 mg) drove facial and total body repigmentation in nonsegmental vitiligo, with similar serious adverse event rates to placebo—an important step toward faster, systemic options. HIV Research Roadmap: NIH released its FY2026–2030 strategic plan for HIV and HIV-related research, setting priorities across research, capacity, and operations. Prison Healthcare Oversight: The U.S. Supreme Court rejected Arizona’s bid to block a court-appointed receiver from taking over state prison healthcare, keeping the Oct. 19 transition on track. Mental Health Access & Treatment Logistics: Coverage highlights accelerated TMS approaches for severe depression and the need to match treatment intensity to real-world patient needs. Public Health & Vaccines: The NHS began offering flu jabs to homeless people via pop-ups and mobile vans, while Pennsylvania reported a fifth measles death as cases near 1,000. Healthcare Workforce Pressure: Iran’s nurses’ council blames authorities for resignations tied to pay, overtime, and workplace discrimination. Policy Fight Over Costs: California’s Prop 40 would tax billionaires to fund healthcare, but major groups warn about safeguards and spending rules. Safety & Industry: Deadly boiler explosions at TIL Healthcare’s Sri City plant killed workers and triggered inquiries. Opioid Threat: A pilot study in Estonia found cychlorphine detected in half of synthetic-opioid users, pointing to widespread misidentification and substitution.